Halozyme Announces argenx Has Selected Second Target Under ENHANZE(R) Technology Collaboration And License Agreement

Triggers $10 million milestone payment to Halozyme in the second quarter SAN DIEGO, May 22, 2019 -- (Healthcare Sales & Marketing Network) -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-deliver... Biopharmaceuticals, Drug Delivery, Licensing Halozyme Therapeutics, argenx , ENHANZE
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news